JPMorgan Chase & Co. Boosts Holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

JPMorgan Chase & Co. boosted its holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 244.3% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 274,693 shares of the company's stock after buying an additional 194,913 shares during the period. JPMorgan Chase & Co. owned 0.32% of IDEAYA Biosciences worth $7,060,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. Barclays PLC boosted its stake in IDEAYA Biosciences by 188.8% in the 3rd quarter. Barclays PLC now owns 181,170 shares of the company's stock worth $5,739,000 after purchasing an additional 118,438 shares during the period. Geode Capital Management LLC grew its position in shares of IDEAYA Biosciences by 9.8% during the third quarter. Geode Capital Management LLC now owns 1,945,455 shares of the company's stock valued at $61,645,000 after purchasing an additional 172,838 shares in the last quarter. SG Americas Securities LLC increased its holdings in shares of IDEAYA Biosciences by 444.2% in the fourth quarter. SG Americas Securities LLC now owns 18,486 shares of the company's stock worth $475,000 after purchasing an additional 15,089 shares during the last quarter. WCM Investment Management LLC purchased a new stake in shares of IDEAYA Biosciences in the fourth quarter worth about $6,030,000. Finally, abrdn plc boosted its stake in IDEAYA Biosciences by 31.7% during the fourth quarter. abrdn plc now owns 306,723 shares of the company's stock valued at $7,883,000 after buying an additional 73,893 shares during the last quarter. 98.29% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on IDYA shares. Stephens restated an "overweight" rating and set a $50.00 price objective on shares of IDEAYA Biosciences in a research report on Friday, February 14th. Royal Bank of Canada restated an "outperform" rating and set a $61.00 price target on shares of IDEAYA Biosciences in a report on Wednesday, January 15th. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating on shares of IDEAYA Biosciences in a research note on Monday, January 13th. Two investment analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $53.58.

IDEAYA Biosciences Stock Up 2.5 %

IDYA traded up $0.45 on Tuesday, reaching $18.63. 1,771,999 shares of the company traded hands, compared to its average volume of 947,694. The company has a market cap of $1.63 billion, a P/E ratio of -5.65 and a beta of 0.51. IDEAYA Biosciences, Inc. has a one year low of $13.45 and a one year high of $44.42. The firm has a fifty day simple moving average of $18.11 and a two-hundred day simple moving average of $23.65.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last announced its quarterly earnings results on Thursday, February 13th. The company reported ($1.49) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.67) by ($0.82). The company had revenue of $7.00 million during the quarter, compared to analysts' expectations of $7.00 million. On average, equities analysts forecast that IDEAYA Biosciences, Inc. will post -3.07 earnings per share for the current year.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.